CLPBF (Coloplast AS) LT-Debt-to-Total-Asset: 0.47 (As of Mar. 2026)

What is Coloplast AS LT-Debt-to-Total-Asset?

Coloplast AS CLPBF 72 LT-Debt-to-Total-Asset is 0.47 as of Mar. 2026. GuruFocus rates CLPBF with a GF Score™ of 72/100 and a GF Value™ of $125.62 (Significantly Undervalued). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Coloplast AS's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.47.

Coloplast AS's long-term debt to total assets ratio increased from Mar. 2025 (0.35) to Mar. 2026 (0.47). It may suggest that Coloplast AS is progressively becoming more dependent on debt to grow their business.

Coloplast AS (OTCPK:CLPBF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Coloplast AS LT-Debt-to-Total-Asset Related Terms

Coloplast AS LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Coloplast AS's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coloplast AS LT-Debt-to-Total-Asset Chart

Coloplast AS Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.45

0.25

0.36

0.42

Coloplast AS Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.35	0.36	0.42	0.44	0.47

72GF Score

Coloplast AS CLPBF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Coloplast AS LT-Debt-to-Total-Asset Calculation

Coloplast AS's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (A: Sep. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2025 )	/	Total Assets (A: Sep. 2025 )
	=	3152.854	/	7606.07
	=	0.41

Coloplast AS's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	3402.162	/	7215.288
	=	0.47

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.47 mean?

Coloplast AS (CLPBF) has a LT-Debt-to-Total-Asset of 0.47 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Coloplast AS and its competitors.

Is Coloplast AS's LT-Debt-to-Total-Asset too high?

Coloplast AS's current LT-Debt-to-Total-Asset is 0.47. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Coloplast AS's LT-Debt-to-Total-Asset compare to ISRG and BDX?

Coloplast AS's LT-Debt-to-Total-Asset of 0.47 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Coloplast AS and its competitors. Coloplast AS's current LT-Debt-to-Total-Asset is 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Coloplast AS stock overvalued right now?

Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $125.62, compared to a current price of $57.41 — trading 54.3% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.47. Coloplast AS's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current LT-Debt-to-Total-Asset is 0.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coloplast AS (CLPBF) Overvalued in 2026?

Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued. The current stock price of $57.41 is trading 54.3% below its estimated GF Value™ of $125.62. GuruFocus considers Coloplast AS to be Significantly Undervalued.

Key valuation signals for CLPBF:

LT-Debt-to-Total-Asset: 0.47
GF Value™: $125.62 vs. price of $57.41 (54.3% below fair value)
GF Score™: 72/100 with 7 warning signs

No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coloplast AS Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies OCSE:DEMANT OCSE:AMBU B OCSE:GN OCSE:EMBLA OCSE:CHEMM OCSE:VIRO OCSE:SMSMED ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST XSWX:STMN TSE:4543 XPAR:DIM COO SOLV

Other Exchanges CLPBY:USA COLOBc:UK 0QBO:UK COLO B:Denmark CBHD:Germany COLO:Austria

Address Holtedam 1-3, Humlebaek, DNK, DK-3050

Website https://www.coloplast.com

Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

72GF Score

Get the complete analysis for CLPBF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$57.41

Price

$125.62

GF Value

View CLPBF Analysis

See LT-Debt-to-Total-Asset data for all stocks →